Elicio Therapeutics: H.C. Wainwright cuts target price to $21 from $23
ELTX•H.C. Wainwright cut its target price for Elicio Therapeutics to $21 from $23.
Related News
ABM expands Phoenix Suns, Mercury partnership with three-year agreement
ABM•
Venture Global secures $3 billion revolving credit facility
VG•
Arbutus Biopharma swings to Q3 net income of $59.12 million
ABUS•
Mirum's brelovitug meets primary endpoint in Phase 3 hepatitis delta trial
MIRM•
Sionna Therapeutics posts higher-than-expected Q3 net loss on restructuring costs
SION•